Residual insulin secretion in insulin dependent diabetes mellitus

S ROGERS AND M SILINK

Department of Endocrinology, Royal Alexandra Hospital for Children, Camperdown, Australia

SUMMARY The residual insulin secretory capacity of 244 children with insulin dependent diabetes mellitus was determined by measurement of their 24 hour urinary C peptide excretion. An inverse linear relation was found between the residual B cell secretion and the duration of diabetes. The age at onset of diabetes did not affect the residual B cell function significantly.

The residual insulin secretory capacity of patients with insulin dependent diabetes mellitus can be determined by measurement of their 24 hour urinary C peptide excretion. This has been shown to be a valid index of integrated B cell function in diabetic patients and is unaffected by the presence of exogenous insulin and insulin antibodies. Most studies of residual insulin secretion in diabetes mellitus have reported plasma C peptide determinations and basal or post-stimulatory measurements, or both. The studies of 24 hour urinary C peptide excretion have either been reported in adults or in small studies in children. We present results of measurements of urinary C peptide in 244 patients attending the Royal Alexandra Hospital for Children over the past five years to determine the effect of duration of diabetes and age at diagnosis on the residual insulin secretory capacity.

Patients and methods

Twenty four hour urinary C peptide excretion was determined in 244 children with insulin dependent diabetes mellitus. There were 123 boys and 121 girls aged between 0.2 and 19.3 years (mean 11.3 years). A histogram depicting the age distribution for both boys and girls is shown in Fig. 1. The duration of diabetes ranged from the initial diagnosis up to 17.1 years (mean 4.1 years). Control values were determined in 47 healthy non-diabetic children aged 3.0 to 16.2 years (mean 12.1 years).

Twenty four hour urine samples were collected in plastic containers without preservatives and kept refrigerated during the collection period. They were then stored at -20°C until ready for assay at which time they were centrifuged to remove sediment. The C peptide immunoreactivity was measured using a double antibody radioimmunoassay kit (either Immunonuclear or Daiichi) for human C peptide that uses rabbit antiserum prepared against residues 33 to 63 of the human proinsulin molecule. Urine samples were diluted as necessary with the assay buffer. The lower limit of sensitivity of the assay was 0.1 pmol/ml. Low, medium, and high urine controls gave intra-assay coefficients of variation of 3.0%, 7.3%, and 8.3% respectively, and interassay coefficients of variation of 6.6%, 6.9%, and 12.5% respectively. Creatinine concentrations were determined in the urine specimens by the alkaline picrate method.

Results

The relation between urinary C peptide excretion and duration of diabetes in the 244 patients is shown in Fig. 2. During the first year of diabetes, 24% of patients had C peptide values within the non-diabetic range of 0.83 to 5.80 pmol C peptide/μmol creatinine per day (mean (SD) 2.07 (1.08)). The mean C peptide excretion for each yearly interval from 0 to 10 years' duration of diabetes was calculated and an inverse linear correlation between the residual B cell function and duration of diabetes was found. The regression line is defined by the equation \( y = -8.52 + (0.66) \) with a correlation coefficient \( r \) equal to 0.86, a highly significant correlation (\( P < 0.001 \)). A urinary C peptide value of 0.2 pmol C peptide/μmol creatinine per day, which is approximately 10% of the non-diabetic mean value, was considered to be an inadequate (as exogenous insulin is necessary) but significantly measurable amount. This cut off value was also used by Crossley et al. The percentage of patients at varying duration of diabetes who had urinary
Fig. 1 Age distribution of diabetic patients.

Fig. 2 Twenty four hour urinary C peptide values for the 244 patients investigated plotted against duration of disease.
C peptide values greater than or equal to 0.2 pmol C peptide/μmol creatinine per day is given in Fig. 3. During the first three years there is a noticeable decrease in the number of patients with urinary C peptide excretion above this value falling to a very low percentage after six years.

The relation between B cell secretion after diagnosis and the age of the patient at the onset of diabetes was investigated. A multiple regression analysis of the urinary C peptide excretion, age at onset of diabetes, and the duration of diabetes showed that the age at onset did not have an effect at the 0.20 significance level.

Discussion

We have found that 24 hour urinary C peptide determinations are a convenient and non-invasive measure of residual insulin secretory capacity and because of this are useful to monitor changes in B cell activity during the course of insulin dependent diabetes mellitus. They are particularly useful in childhood diabetes where there is considerable patient resistance to repeated blood sampling. It is also possible for the urine samples to be collected at home and kept frozen until they can be brought in at the next visit to the doctor. The assay becomes limited in its usefulness only if and when the diabetic patient develops glomerular filtration problems leading to renal failure. As with previous workers, we have found that the urinary C peptide value is best expressed in relation to creatinine. The absolute amount of C peptide excreted per day may be of interest, but as it correlates with body weight it is of limited use for studying a group of children of varying age and size.

A significant correlation was found between the mean urinary C peptide excretion and the duration of diabetes, although there was a large scatter of urinary C peptide values in the first two years, as seen in Fig. 2. This makes it impossible to use this correlation as a predictor of residual B cell function for an individual, but shows clearly the trend for the diabetic population. The urinary C peptide value measured during the first year of diabetes mellitus reflected a substantial insulin secretory capacity in most patients studied, with values within the normal range not uncommon. A significant urinary C peptide value (greater or equal to 0.2 pmol/μmol creatinine per day) was found in 70% of patients in the first year, 42% in the second year, and 20% in the third year. In the first five years of diabetes mellitus significant B cell secretion as thus defined was found in approximately 35% of patients. If we consider residual B cell function present when post stimulatory plasma C peptide values were equal to or exceeded the effective detection limit of the assay, which was 0.06 pmol/ml. Crossley et al reported a much lower incidence of residual B cell function with 66% of patients having a urinary C peptide excretion less than 0.20 pmol/μmol creatinine per day during the 12 months after diagnosis.

We were unable to show that the age of the patient at onset of diabetes had a significant effect at the P=0.20 level on the residual B cell secretion after diagnosis. In contrast Crossley et al reported a significant correlation between age at onset and the urinary C peptide value at both one year and two years after diagnosis in 25 children investigated. Other investigators measuring serum immunoreactive C peptide had reported the higher prevalence of residual B cell function in patients diagnosed at a later age than those with early onset diabetes mellitus. Madsbad et al compared patients diagnosed between 10 and 19-9 years and 30 and 39-9 years and found a higher prevalence of residual B cell secretion in the later onset group when comparing patients of similar duration of disease up to 15 years. From our own studies we are unable to conclude that the age of onset of diabetes influences the residual insulin secretory capacity of B cells, though it may well have a subtle influence which is only evident when comparing patients with a disease onset greater than 10 years apart.

This project was supported by donations from Mr R Williams and...
Residual insulin secretion in insulin dependent diabetes mellitus

Mr C E Heath Group of Companies. We thank Mrs A Russell for her assistance.

References


Correspondence to Mrs S Rogers, Department of Endocrinology, Royal Alexandra Hospital for Children, Bridge Road, Camperdown, N.S.W. 2050, Australia.

Received 3 December 1984